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Cancer therapeutics are complex, constantly evolving, and aim to prolong the life of a patient with 
cancer by cure, inducing remission, or by slowing disease progression. Cancer treatments can be 
delivered locally directly against the tumour (i.e. surgery or radiotherapy) or systemically (i.e. 
chemotherapy, hormone therapy). Systemic therapies have traditionally been administered 
intravenously in a hospital or day unit setting; however many of the more recently discovered 
systemic cancer therapies are taken as an oral medication. They also pose significant potential risks 
to a patient’s health through side effects, immunosuppression, and later development of secondary 
cancers. 
 
This article focusses on systemic cancer therapies from a primary care perspective. Recent 
developments and classifications of systemic therapies are briefly presented. Key considerations 
around monitoring, potential treatment harms, and patient support are discussed to inform the 
delivery of primary care for cancer patients receiving systemic therapies. 
 
Systemic therapies 
The breadth of cancer treatments available continues to grow over time, as new treatments move 
from the bench to the bedside, and into clinical practice. New classes of cancer therapeutics, such as 
immunotherapy and targeted therapy, have improved cancer outcomes for patients with certain 
tumours that previously held very poor prognoses (e.g. metastatic malignant melanoma or lung 
adenocarcinoma). Table 1 shows the broad treatment types available, and some of the more 
common sub-types. 
 
The classes of systemic cancer therapies include1–4  
Chemotherapy – medications delivered in a number of ways (orally, intravenous, topical, 
intramuscular, intracavitary) that inhibit the cell cycle, exploiting the fact that cancer cells 
generally divide more rapidly than normal cells. The non-specific nature of the treatments 
mean cells in tissue other than the cancer are also affected, particularly more rapidly 
dividing cells such as those found in the skin and gut. The efficacy of chemotherapy is 
variable, and some cancers can become chemoresistant (where the tumours cells have a 
reduced response to the therapy). 
Targeted therapy – treatments that target specific genes, cell signalling pathways, or 
proteins that are unique to cancer cells or to the cellular environment that enable tumour 
growth to occur. Targeted therapies provide benefit by affecting primarily abnormal cancer 
cells, while minimising the effects or normal cells. These medications are most commonly 
administered orally, and usually metabolised by the liver. 
Immunotherapy – a range of treatments that enable or enhance the ability of the patient’s 
own immune system to identify and eliminate cancer cells within the body. This can be 
achieved using several techniques, including vaccines, antibodies, and oncolytic viruses. 
Hormone therapy – the development and progression of breast cancer in women and 
prostate cancer in men is often influenced by hormones. There are some other cancer types 
(e.g. ovarian, endometrial) that have a lesser, but still important, response to the hormonal 
environment in the body. Hormone therapy can be used for primary treatment of 
advanced/metastatic cancer, as an adjuvant to reduce the risk of recurrence, or 
neoadjuvantly to reduce tumour size prior to localised treatments. 
Stem cell/Bone marrow transplant – haematological cancers can be treated by eliminating a 
patient’s bone marrow with intensive chemotherapy and other treatments, and then 
replacing it with their own cells (autologous) or another person’s cells (donor). 
 
Chemotherapy 
 IV cytotoxics Anthracyclines (e.g. Doxorubicin) 
Antibiotics (e.g. Bleomycin) 
Platinum drugs (e.g. Cisplatin) 
 Oral alkylating 
agents 
e.g. Temozolomide, Chlorambucil, 
Cyclophosphamide, Lomustine, Melphalan 
 Oral 
antimetabolites 
e.g. Capecitabine, Hydroxycarbamide, 
Mercaptopurine, Tioguanine, Methotrexate 
Targeted therapies 
 Growth Inhibitors Tyrosine kinase inhibitors (e.g. Imatinib) 
Proteasome inhibitors (e.g. Bortezomib) 
mTOR inhibitors (e.g. Everolimus) 
 Anti-VEGF e.g. Bevacizumab 




Immunotherapy (or biologic therapy) 
 Monoclonal 
antibodies 
e.g. Rituximab, Trastuzumab 
 Checkpoint 
inhibitors 
Programmed cell death protein 1 (PD-1) (e.g. 
Nivolumab) 
Programmed death ligand 1 (PD-L1) (e.g. 
Atezolizumab) 





LHRH agonist (e.g. Goserelin) 
Non-steroidal anti-androgen (e.g. Bicalutamide) 
Steroidal anti-androgen (e.g. Cyproterone acetate) 
Antiandrogen synthesis inhibitor (e.g. Abiraterone 
acetate) 







e.g. Anastrazole, Letrozole, Exemestane 
Stem cell or bone marrow transplant 
 Autologous 
 Donor 
Table 1 – Categories of systemic cancer therapies, with some examples 
 
Prescribing in primary care 
Systemic cancer therapies are most often prescribed by secondary or tertiary care clinicians, and 
administered in inpatient and/or outpatient settings. Clear communication between oncology teams 
and primary care is vital to maintain accurate, contemporary records and to prevent drug-drug 
interactions from any new prescriptions initiated in primary care. These interactions may reduce the 
effectiveness of the cancer treatment or induce unwanted side effects. 
 
Hormone therapies are often prescribed and administered in primary care for breast cancer in 
women and prostate cancer in men. They are usually commenced by the patient’s oncologist or 
surgeon, and once the patient is stable GPs are asked to continue the prescription and treatment 
monitoring for these patients for a specified length of time. For women, hormone therapy has been 
shown to reduce breast cancer mortality and risk of recurrence5. Tamoxifen is given as an adjuvant 
treatment for pre-menopausal women, with chemical or surgical ovarian suppression for high-risk 
women. Postmenopausal women are often offered an Aromatase Inhibitor. A woman may be 
recommended to receive hormone therapy for 2-10 years, depending on the indication and other 
treatments given. For men, androgen deprivation can improve survival in the adjuvant setting, and 
slow disease progression for advanced stage cancers6. Hormone therapy is not a primary treatment 
for localised prostate cancer. The length of hormone therapy treatment for men can also vary, 
depending on the indication. It could be delivered intermittently, or by depot injection, if the man 
will be receiving it long-term. 
 
There are a number of important health impacts and side effects experienced by women receiving 
hormone therapy that prescribers need to be aware of, and to mitigate where possible5. Aromatase 
Inhibitors (e.g. Letrozole) can have the following effects  
Osteoporosis and bone fractures – oestrogen deficiency leads to increased bone resorption, 
putting these women at increased risk of osteoporotic fractures. Baseline bone density 
measurement with dual-energy x-ray absorptiometry (DEXA) is advised, and repeat 
monitoring depends on the woman’s menopausal status and treatment regime7. All women 
should aim for at least 800IU of Vitamin D3 and 1200mg of total calcium in their diet per day. 
Postmenopausal women and premenopausal women undergoing ovarian suppression 
should be recommended osteoporosis treatment (e.g. Zolendronic acid). 
Sexual dysfunction – oestrogen deficiency can also lead to vaginitis, dyspareunia, recurrent 
cystitis, and decreased libido. Sexual dysfunction is often a complex issue that is under-
reported, requiring a varied approach to help patients maintain their sexual relationships. In 
addition to recommending lubricants and dietary supplements, patients may benefit from 
psychosexual counselling. 
Musculoskeletal problems – arthralgia, myalgia, tendinitis and carpal tunnel syndrome have 
all been reported by patients receiving hormone therapy. Following discussion with the 
oncologist, switching to an alternative aromatase inhibitor may help alleviate symptoms. 
Usual primary care management of musculoskeletal problems, such as anti-inflammatories, 
exercise, or possibly acupuncture may also prove to be of some benefit. 
Cardiovascular disease (CVD) risk – women with oestrogen deficiency are at increased risk of 
hypertension and hyperlipidaemia, potential raising their risk of cardiovascular disease. 
Close monitoring and management of CVD risk factors in primary care is needed. 
 
The more common adverse effects of Tamoxifen, and other anti-androgens, include the following5  
Hot flushes – a very common side effect of Tamoxifen. Conservative management includes 
loose, light clothing and bed covers. Patients can be co-prescribed an SSRI or SNRI, but 
strong CYP2D6 inhibitors such as paroxetine or fluoxetine should be avoided to prevent 
reducing the efficacy of Tamoxifen. 
Venous thromboembolism (VTE) – patients receiving anti-androgens are at a 2-3 times higher 
risk of VTE, particularly in prolonged courses of hormone therapy (>5 years). Caution should 
be taken in patients with non-cancer related risk factors for VTE. 
Endometrial cancer – any patients on Tamoxifen with features of possible endometrial 
cancer, such as abnormal vaginal bleeding, should be promptly investigated due to an 
increased risk of these cancers. 
Ocular pathology – Tamoxifen increases the risk of cataracts and other ocular pathologies 
that can affect vision. Patients exhibiting any visual symptoms should be assessed in primary 
care and/or the patient’s optometrist. 
 
Androgen Deprivation Therapy (ADT) for men with prostate cancer can have physical and 
psychological effects on patients, including the following8   
Osteoporosis – though this is a less recognised health issue for older men relative to women, 
reduced bone mineral density can occur in men receiving ADT. Baseline bone density 
monitoring would ideally be performed. Men should also be advised to consume at least 
800IU of Vitamin D3 and 1200mg of total calcium as part of their diet per day. The decision 
to commence bisphosphonate therapy will depend on a patient’s risk of osteoporotic 
fracture, which can be calculated using the FRAX or QFracture scores. 
Sexual dysfunction – men on ADT commonly experience reduced libido and/or erectile 
dysfunction (ED). A trial of a Phosphodiesterase type 5 (PDE5) inhibitor is recommended. 
Psychosexual counselling may be beneficial for some men, and referral to urology for 
consideration of other ED treatments may be warranted if there is no improvement in 
symptoms. 
Hot flushes – vasomotor symptoms are common for men on ADT, and can persist for years, 
even after completion of treatment. Medroxyprogesterone (20mg once daily) can be trialled 
for a minimum of 10 weeks to help manage symptoms. Cyproterone acetate (50mg twice 
daily for 4 weeks) is an alternative if medroxyprogesterone is not effective or not tolerated. 
Anaemia – ADT can result in a normocytic, normochromic anaemia. Routine monitoring is 
not recommended, but this effect should be considered if men become symptomatic (e.g. 
exertional dyspnoea) or an incidental anaemia is found. 
 
Systemic cancer drug-related problems  
There are a number of potential drug-related problems to consider for patients taking systemic 
cancer therapies9. The side effect profile of each drug will vary, but there are some side effects 
which are common to many systemic cancer therapies. There are also some severe adverse effects 
of cancer treatments that primary care professionals need to be aware of and act on urgently (see 
table 2).  
 
Common, seldom severe Common, potentially severe Uncommon, severe 
Fatigue Vomiting Venous Thromboembolism 
Nausea Diarrhoea Febrile neutropaenia 
Mucositis Rash Tumour lysis syndrome 
Constipation Pain Hyperuricaemia, renal failure 
Hair loss Neuropathy Teratogenicity 
Skin erythema  Cardiomyopathy 
Table 2 – More common adverse effects of systemic cancer therapies 
 
Patients and their partners/carers can be empowered to monitor, manage, and report their 
symptoms with the provision of good quality treatment information, and symptom reporting tools 
(see figure 1 for an example). 
 
 
Figure 1 – Traffic light symptom reporting tool (reproduced from the National Chemotherapy Board 
Good Practice Guidelines [2016]10) 
 
Drug interactions are a significant potential problem for cancer patients. Estimates of the prevalence 
of potential drug-drug interactions for cancer patients receiving systemic therapy range from 17 – 
46%11,12.  These drug interactions particularly affect older cancer patients, who are more likely to 
have multiple co-morbidities and take multiple long-term medications. Risk factors for drug 
interactions are listed in Table 3. These challenges re-emphasise the importance of clear 
communication between primary care and oncology teams to ensure anyone prescribing a new 
medication for a cancer patient is clear on what systemic therapies they are receiving and what their 
regular medications are. 
  
Risk factors for drug interactions 
Older age 
Polypharmacy 
Low body weight 
Renal impairment 
Haematologic cancer 
Multiple medical co-morbidities 
Longer hospital stays 
History of adverse drug reactions 
Intake of highly protein bound drugs 
  
Table 3 – Risk factors for drug interactions from Campen et al13 
 
Each type of systemic cancer therapy has their own known drug-drug interactions, as well as 
potential interactions with over-the-counter (OTC) medications, alternative therapies, and foods. 
There are some more common potential drug-drug interactions to be aware of when prescribing in 
primary care13,14 = 
Cytochrome P450 inhibitors/inducers – drugs that competitively inhibit (e.g. Ciprofloxacin) or 
induce (e.g. Phenytoin) cytochrome P450 binding sites can have an impact on the efficacy 
and safety of a number of oral and intravenous systemic cancer therapies, including Tyrosine 
Kinase Inhibitors (TKIs), SERMs and ADT agents. 
Gastric acid suppression – H2-antagonists (e.g. Ranitidine) and Proton Pump Inhibitors 
[(PPIs) e.g. Omeprazole] alter the gastric pH, which can affect the absorption and 
bioavailability of oral systemic cancer therapies. If a patient is symptomatic and needs acid 
suppression, taking these medications at least two hours before or after their oral cancer 
treatment may reduce their impact on drug absorption. 
Anticoagulants – Some oral systemic cancer therapies, such as Ibrutinib (a TKI), can increase 
the INR and cause bleeding. Patients taking oral anticoagulants (e.g. Warfarin) for other 
indications, such as atrial fibrillation, will need careful assessment of the risks and benefits of 
both treatments, and close monitoring. 
QTc prolongation – A number of targeted therapies are known to cause QTc prolongation 
(e.g. Sorafenib, Sunitinib), perhaps provoking serious arrhythmias. Prescribers giving long-
term (e.g. amitriptyline) or short-term (e.g. clarithromycin) medications that can also affect 
the QT interval need to be aware of the possibility of drug-drug interaction, prolonging the 
QT interval. 
 
Optimising primary care for cancer patients 
Supporting cancer patients receiving systemic cancer therapies optimally requires a multidisciplinary 
approach that includes primary care. The treatment journey for these patients can have physical, 
psychological, social and emotional effects. Some patients will recover from treatment with the 
cancer in remission or cured, but many will need further treatment with curative intent or for 
palliation if there is disease progression in spite of treatment. Primary care plays a key role in 
identifying and managing physical effects of treatment, providing psychosocial support, and 
arranging specialist review where needed. Regular and accurate communication is critical to ensure 
all professionals involved in the patient’s care are informed of current and planned treatments, and 
to avoid preventable adverse drug reactions. 
 
Word count – 1990/2000 
 
References 
1.  CRUK. Treatment for cancer. https://www.cancerresearchuk.org/about-cancer/cancer-in-
general/treatment. Published 2020. Accessed May 11, 2020. 
2.  Philip L, Renius K, LaPointe S. Exploring common drug interactions with oral oncology agents. 
Pharm Today. 2018;24(4):44-45. doi:10.1016/j.ptdy.2018.03.028 
3.  Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and 
challenges ahead. J Cancer Metastasis Treat. 2017;3(10):250-261. doi:10.20517/2394-
4722.2017.41 
4.  Padma VV. An overview of targeted cancer therapy. Biomedicine. 2015;5(4):1-6. 
5.  Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. Curr 
Oncol. 2018;25(4):285-291. doi:10.3747/co.25.4139 
6.  Abraham J, Staffurth J. Hormonal therapy for cancer. Medicine (Baltimore). 2011;39(12):723-
727. doi:10.1016/j.mpmed.2011.09.006 
7.  Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer 
treatment-induced bone loss: A consensus position statement from a UK Expert Group. 
Cancer Treat Rev. 2008;34(SUPPL. 1):S3-S18. doi:10.1016/j.ctrv.2008.03.007 
8.  Noonan EM, Farrell TW. Primary care of the prostate cancer survivor. Am Fam Physician. 
2016;93(9):764-770. 
9.  Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising treatment-associated risks in 
systemic cancer therapy. Pharm World Sci. 2008;30(2):161-168. doi:10.1007/s11096-007-
9157-4 
10.  Oakley C, Chambers P, Board R, et al. Promoting Early Identification of Systemic Anti-Cancer 
Therapies Side Effects: Two Approaches. In: National Chemotherapy Board GOOD PRACTICE 
GUIDELINE. ; 2016. 
11.  Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential Drug-Drug and Herb-Drug 
Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance. J Oncol 
Pract. 2017;13(7):e613-e622. doi:10.1200/jop.2017.020859 
12.  Van Leeuwen RWF, Brundel DHS, Neef C, et al. Prevalence of potential drug-drug interactions 
in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071-1078. 
doi:10.1038/bjc.2013.48 
13.  Campen CJ, Vogel WH, Shah PJ. Managing Drug Interactions in Cancer Therapy: A Guide for 
the Advanced Practitioner. J Adv Pract Oncol. 2017;8(6):609-620. 
doi:10.6004/jadpro.2017.8.6.4 
14.  Conde-Estévez D. Targeted cancer therapy: interactions with other medicines. Clin Transl 
Oncol. 2017;19(1):21-30. doi:10.1007/s12094-016-1509-x 
 
